The company
Intelligent Bio Solutions Inc.
INBS · Nasdaq
INBS stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 37.3% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 52
- Industry in uptrend
- 27% -9 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $0
- Officials’ trades on record
- 0
- Institutions holding
- 8 (-1)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.
Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
No open-market buy or sale by its insiders on record.
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| ARMISTICE CAPITAL, LLCadded · filed 14 Aug 2026 | 141,397$325K | +11,397+8.8% |
| GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026 | 20,840$48K | -7,769−27.2% |
| VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 2026 | 5,810$13K | 00.0% |
| UBS Group AGadded · filed 13 Aug 2026 | 5,735$13K | +5,363+1441.7% |
| VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 2026 | 3,958$9,084 | 00.0% |
| Tower Research Capital LLC (TRC)added · filed 11 Aug 2026 | 3,280$7,528 | +2,030+162.4% |
| OSAIC HOLDINGS, INC.unchanged · filed 14 Aug 2026 | 200$460 | 00.0% |
| BARCLAYS PLCnew · filed 14 Aug 2026 | 142$326 | +142 |
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.